New dosing strategy tested to fight tough myeloma with fewer side effects
NCT ID NCT05847569
Summary
This study is testing if different doses and timing of the drug belantamab mafodotin can work better for people with multiple myeloma that has come back or stopped responding to other treatments. The drug is designed to target and kill myeloma cells. Researchers want to see if these new dosing plans can control the cancer while reducing serious eye-related side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mayo Clinic in Florida
RECRUITINGJacksonville, Florida, 32224-9980, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.